Search Results
Your search for Matthew Stenger matches 7239 pages
Showing 301 - 350Pertuzumab/Trastuzumab for Nonindicated HER2-Altered Advanced Solid Tumors: MyPathway Update
In an updated analysis of a cohort in the phase IIa MyPathway study published in the Journal of Clinical Oncology, Christopher J. Sweeney, MBBS, and colleagues described outcomes with the combination of pertuzumab and trastuzumab in nonindicated HER2-altered advanced solid tumors. As stated by the ...
Individualized SABR for Lung Tumors
In a phase II study (iSABR) reported in JAMA Oncology, Gensheimer et al found that individualized stereotactic ablative radiotherapy (SABR) for up to four lung cancer tumors was associated with a high degree of local control and the ability to minimize radiation doses. Study Details Two hundred and ...
Small Breast Cancer: Omission of Axillary Surgery vs Sentinel Lymph Node Biopsy
In a noninferiority phase III trial (SOUND) reported in JAMA Oncology, Gentilini et al found that no axillary surgery was noninferior to sentinel lymph node biopsy (SLNB) in terms of distant disease–free survival among patients with small breast cancer and negative findings on preoperative...
Isa-KrD for Transplant-Eligible and -Ineligible High-Risk Newly Diagnosed Multiple Myeloma
In an interim analysis of a German phase II trial (MMG-CONCEPT) reported in the Journal of Clinical Oncology, Leypoldt et al found that Isa-KrD (isatuximab, carfilzomib, lenalidomide, and dexamethasone) produced high rates of measurable residual disease (MRD) negativity newly diagnosed patients...
Addition of Lapatinib to Chemoradiotherapy in Non–HPV-Related Head and Neck Cancer
In a phase II trial (RTOG 3501, TRYHARD) reported in JAMA Oncology, Wong et al found that the addition of lapatinib to chemoradiotherapy with cisplatin did not appear to improve progression-free survival in front-line therapy for stage III to IV non–human papillomavirus (HPV)-related head and neck...
ShortHER Update: 10-Year Survival Outcomes With 9 Weeks vs 1 Year of Adjuvant Trastuzumab in HER2-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by PierFranco Conte, MD, PhD, and colleagues, the final analysis of the Italian phase III noninferiority ShortHER trial showed little difference in 10-year disease-free survival and overall survival with 9 weeks vs 1 year of adjuvant trastuzumab in...
Addition of SBRT to Abiraterone Acetate in Oligometastatic Castrate-Resistant Prostate Cancer
In an Italian phase II trial (ARTO) reported in the Journal of Clinical Oncology, Francolini et al found that the addition of stereotactic body radiation therapy (SBRT) to first-line abiraterone acetate and prednisone resulted in a significantly higher rate of biochemical response among patients...
Tucatinib/Trastuzumab for Previously Treated Patients With HER2-Positive Metastatic Biliary Tract Cancer
As reported in the Journal of Clinical Oncology by Nakamura et al, findings in a cohort of the phase II SGNTUC-019 basket study showed that tucatinib plus trastuzumab was active in previously treated patients with HER2-positive metastatic biliary tract cancer who had not received prior...
Prophylactic Radiation for High-Risk Asymptomatic Bone Metastases
In a phase II trial reported in the Journal of Clinical Oncology, Erin F. Gillespie, MD, MPH, and colleagues found that prophylactic radiotherapy in patients with high-risk asymptomatic bone metastases from solid tumors reduced the risk of skeletal-related events compared with standard of care. A...
Postdiagnosis Exercise and Mortality Risk Among Patients With Cancer
In a study reported in the Journal of Clinical Oncology, Lavery et al found that long-term cancer survivors who engaged in postdiagnosis exercise consistent with national guidelines had reduced all-cause mortality, with reductions seen in both cancer and noncancer mortality. Key Findings The study...
Ambulatory Thromboprophylaxis in Patients With Lung and Gastrointestinal Cancers
In an Australian phase III trial (TARGET-TP) reported in JAMA Oncology, Alexander et al found that ambulatory thromboprophylaxis reduced the risk of thromboembolic events in patients starting systemic therapy for lung or gastrointestinal cancer who were at elevated risk of thrombosis. Study ...
Effect of Travel Time and Distance to Cancer Center on Participation of Patients in Genotype-Matched Trials
In a Japanese study reported in JAMA Network Open, Uehara et al found that travel time to the National Cancer Center Hospital (NCCH) in Tokyo affected the participation of referred patients with cancer in genotype-matched clinical trials. Study Details The retrospective cohort study, performed...
Quality of Life With Nivolumab Plus Chemotherapy in Advanced Gastric/GEJ Cancer or Esophageal Adenocarcinoma
As reported in the Journal of Clinical Oncology, Markus Moehler, MD, and colleagues found that in the phase III CheckMate 649 trial, the addition of nivolumab to chemotherapy was associated with generally better patient-reported health-related quality of life outcomes in patients with advanced...
First-Line Dabrafenib/Trametinib in Pediatric BRAF V600–Mutated Low-Grade Glioma
In a phase II trial reported in The New England Journal of Medicine, Eric Bouffet, MD, and colleagues found that the combination of dabrafenib and trametinib produced a higher objective response rate vs standard chemotherapy in the first-line treatment of pediatric patients with low-grade glioma...
Carfilzomib and Lenalidomide–Based Therapy in Primary Plasma Cell Leukemia
In a European phase II trial (EMN12/HOVON-129) reported in The Lancet Oncology, van de Donk et al found that the incorporation of carfilzomib and lenalidomide into induction, consolidation, and maintenance therapies was associated with good outcomes in both younger and older patients with primary...
DESTINY-Lung02: T-DXd for HER2-Mutant Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Goto et al, primary results of the phase II DESTINY-Lung02 trial have shown activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (NSCLC) previously treated with platinum-containing...
Addition of Hyperthermic Intraperitoneal Chemotherapy to Interval Cytoreductive Surgery in Advanced Ovarian Cancer
As reported in The Lancet Oncology by Aronson et al, the final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall ...
Hypofractionated vs Conventional Fractionated Proton Radiotherapy After Mastectomy for Breast Cancer
In a phase II trial (MC1631) reported in The Lancet Oncology, Robert W. Mutter, MD, and colleagues found that the 24-month complication rate associated with hypofractionated proton postmastectomy radiotherapy (PMRT) was not noninferior to standard fractionated PMRT in patients undergoing mastectomy ...
Personalized Biomarker-Based Umbrella Trial in Recurrent or Metastatic HNSCC
In a Korean phase II trial (KCSG HN 15-16 TRIUMPH) reported in the Journal of Clinical Oncology, Keam et al described results of a personalized biomarker-driven umbrella trial for the treatment of patients with platinum-refractory recurrent and/or metastatic head and neck squamous cell carcinoma...
Neoadjuvant Chemotherapy Followed by Surgery vs Standard Chemoradiation for Cervical Cancer
In the phase III EORTC-55994 trial reported in the Journal of Clinical Oncology, Kenter et al found no significant difference in overall survival with neoadjuvant chemotherapy followed by surgery vs standard concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical cancer. Study...
Adjuvant Pemetrexed/Cisplatin vs Vinorelbine/Cisplatin in Stage II–IIIA Nonsquamous NSCLC
In a 5-year analysis of the Japanese phase III JIPANG trial reported in the Journal of Clinical Oncology, Kenmotsu et al found no significant differences in overall or recurrence-free survival with adjuvant pemetrexed/cisplatin vs vinorelbine/cisplatin in patients with stage II–IIIA nonsquamous...
Magrolimab Plus Azacitidine in Previously Untreated Patients With AML Ineligible for Intensive Chemotherapy
In a phase Ib study reported in the Journal of Clinical Oncology, Naval G. Daver, MD, and colleagues found that the combination of the anti-CD47 antibody magrolimab and azacitidine was active in previously untreated patients with acute myeloid leukemia (AML) who were ineligible for intensive...
Testicular Cancer: Surveillance vs Chemotherapy After Postchemotherapy RPLND Shows Viable Residual Cancer
In a retrospective study reported in the Journal of Clinical Oncology, Antonelli et al found no difference in outcomes with postsurgical surveillance vs adjuvant chemotherapy after retroperitoneal lymph node dissection (RPLND) showed viable nonteratomatous germ cell tumor in patients who had...
Accelerated Approval Granted for Talquetamab-tgvs in Treatment of Relapsed or Refractory Multiple Myeloma
On August 9, 2023, the bispecific GPRC5D (G protein–coupled receptor, class C, group 5)-directed CD3 T-cell engager talquetamab-tgvs was granted accelerated approval by the U.S. Food and Drug Administration for treatment of adults with relapsed or refractory multiple myeloma who have received at...
Fixed-Dose Niraparib and Abiraterone Plus Prednisone in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On August 11, 2023, the fixed-dose combination of the PARP inhibitor niraparib and the CYP17 inhibitor abiraterone acetate plus prednisone was approved for patients with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer, as determined by a U.S. Food and Drug...
HERTHENA-Lung01: Patritumab Deruxtecan for Advanced EGFR-Mutant NSCLC
In the phase II HERTHENA-Lung01 trial reported in the Journal of Clinical Oncology, Helena Yu, MD, and colleagues found that patritumab deruxtecan (HER3-DXd), a new anti-HER3 antibody-drug conjugate, showed activity in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC)...
First-Line Pembrolizumab Plus Lenvatinib Active in Advanced Non–Clear Cell Renal Cell Carcinoma
In a phase II trial (KEYNOTE-B61) reported in The Lancet Oncology, Laurence Albiges, MD, PhD, of Gustave Roussy, Paris–Saclay University, Villejuif, France, and colleagues found that first-line pembrolizumab plus lenvatinib produced durable responses in patients with advanced non–clear cell renal...
First-Line NALIRIFOX vs Nab-paclitaxel/Gemcitabine in Metastatic Pancreatic Cancer: NAPOLI-3
As reported in The Lancet by Zev A. Wainberg, MD, and colleagues, the phase III NAPOLI-3 trial has shown a modest but significant improvement in overall survival with first-line NALIRIFOX (liposomal irinotecan, oxaliplatin, leucovorin, and fluorouracil) vs nab-paclitaxel and gemcitabine in patients ...
Effect of Diet and Exercise Intervention on Chemotherapy Dose Intensity, Response Rate Among Patients With Breast Cancer
In the LEANer study, reported in the Journal of Clinical Oncology by Tara Sanft, MD, and colleagues, researchers found that an exercise and nutrition intervention did not improve relative dose intensity (RDI) among patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer, but did...
Addition of Olaparib to Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Overall Survival Results in the PROpel Trial
As reported by Fred Saad, MD, and colleagues in The Lancet Oncology, the final prespecified overall survival analysis of the phase III PROpel trial showed no significant benefit with the addition of first-line olaparib to abiraterone in patients with metastatic castration-resistant prostate cancer...
Effect of Adjuvant Metformin on Risk of New Primary Cancers in Patients With Early Breast Cancer
In an analysis from the Canadian Cancer Trials Group MA.32 study reported in the Journal of Clinical Oncology, Pamela Goodwin, MD, MSc, FRCPC, FASCO, and colleagues found that adjuvant metformin did not reduce the risk of new primary invasive cancers vs placebo in patients with early breast cancer. ...
Tisotumab Vedotin–Based Combinations in Advanced Cervical Cancer
In a phase Ib/II study (innovaTV 205/GOG-3024/ENGOT-cx8) reported in the Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, and colleagues found that tisotumab vedotin-tftv combined with carboplatin or pembrolizumab showed activity in both treatment-naive and previously treated patients with ...
Previously Untreated Advanced Melanoma: Addition of Bempegaldesleukin to Nivolumab
In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues found that the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodrug, to nivolumab did not improve treatment outcomes in previously untreated patients with advanced...
Addition of First-Line Regorafenib to Nivolumab and Chemotherapy in Metastatic Esophageal Cancer
In a single-institution phase II study reported in The Lancet Oncology, Cytryn et al found that the combination of regorafenib, nivolumab, and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) showed activity as a first-line treatment regimen for patients with HER2-negative metastatic...
Relapsed Pediatric T-Cell ALL: Base-Edited CAR7 T Cells
In an interim analysis of a small phase I study reported in The New England Journal of Medicine, Chiesa et al found that base-edited CAR7 T cells were active in pediatric patients with relapsed T-cell acute lymphoblastic leukemia (ALL). As stated by the investigators: “Cytidine deamination that is...
Localized Ewing Sarcoma: Interval-Compressed vs Standard-Timing Chemotherapy
As reported in the Journal of Clinical Oncology by Cash et al, 10-year follow-up of the Children’s Oncology Group Study AEWS0031 has shown a maintained event-free survival benefit with interval-compressed chemotherapy vs standard-timing chemotherapy in patients with localized Ewing sarcoma....
PD-L1 Inhibition for Advanced Alveolar Soft-Part Sarcoma
In a phase II trial reported in The New England Journal of Medicine, Chen et al found that atezolizumab produced durable responses in patients with advanced alveolar soft-part sarcoma. As stated by the investigators: “Alveolar soft-part sarcoma is a rare soft-tissue sarcoma with a poor prognosis...
Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer
In the phase III DARS study reported in The Lancet Oncology, Nutting et al found that dysphagia-optimized intensity-modulated radiotherapy (DO-IMRT) was associated with improved patient-reported swallowing function vs standard IMRT in newly diagnosed patients with head and neck cancer. Study...
Selinexor Maintenance Therapy in Advanced or Recurrent Endometrial Cancer
In a phase III study (ENGOT-EN5/GOG-3055/SIENDO) reported in the Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, and colleagues found that a progression-free survival benefit with maintenance selinexor vs placebo after first-line chemotherapy in patients with advanced or recurrent...
Relapsed or Refractory Multiple Myeloma: Mezigdomide Plus Dexamethasone
In a phase I/II trial (CC-92480-MM-001) reported in The New England Journal of Medicine, Paul G. Richardson, MD, and colleagues found that the combination of the novel cereblon E3 ubiquitin ligase modulator mezigdomide and dexamethasone showed activity in heavily pretreated patients with relapsed...
KRAS Wild-Type Advanced Pancreatic Cancer: Addition of Monoclonal Antibody to Chemotherapy
In the Chinese phase III NOTABLE trial reported in the Journal of Clinical Oncology, Shukui Qin, MD, and colleagues examined the addition of the EGFR inhibitor nimotuzumab to gemcitabine in patients with KRAS wild-type locally advanced or metastatic pancreatic cancer. Study Details In the...
Can an Anti-EBV Antibody Assist in Screening for Nasopharyngeal Cancer?
In a Chinese study reported in The New England Journal of Medicine, Li et al found evidence that the anti–Epstein-Barr virus (EBV) anti-BNLF2b total antibody, P85-Ab, may be a promising biomarker for nasopharyngeal cancer screening. Study Details In the study, a peptide library representing highly...
Patients With Cancer and DPYD Variant Alleles: Outcomes With Reduced-Dose Fluoropyrimidine Therapy
In an analysis reported in the Journal of Clinical Oncology, Knikman et al found that reduced doses of fluoropyrimidine therapy in patients with cancer with DPYD variant alleles did not result in poorer outcomes vs DPYD wild-type controls receiving full fluoropyrimidine doses. Study Details The...
Quizartinib in Newly Diagnosed FLT3-ITD–Positive Acute Myeloid Leukemia
On July 20, 2023, quizartinib was approved for use with standard cytarabine and anthracycline induction and cytarabine consolidation and as maintenance monotherapy following consolidation chemotherapy in adults with newly diagnosed acute myeloid leukemia that is FLT3 internal tandem duplication...
Trifluridine/Tipiracil Plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer
On August 2, 2023, the fixed combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, was approved for use with bevacizumab for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based...
Addition of Nivolumab to Stereotactic Ablative Radiotherapy in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC
In a phase II trial (I-SABR) reported in The Lancet, Joe Y. Chang, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the addition of immunotherapy with nivolumab to stereotactic ablative radiotherapy (SABR) improved ...
Dostarlimab-gxly With Chemotherapy for Endometrial Cancer
On July 31, 2023, the immune checkpoint inhibitor dostarlimab-gxly was approved by the U.S. Food and Drug Administration (FDA) for use with carboplatin and paclitaxel, followed by single-agent dostarlimab, for patients with primary advanced or recurrent endometrial cancer that is mismatch...
Neoadjuvant Palbociclib Plus Giredestrant or Anastrozole in ER-Positive, HER2-Negative Breast Cancer
In a phase II study (coopERA Breast Cancer) reported in The Lancet Oncology, Sara A. Hurvitz, MD, and colleagues found that 2 weeks of the addition of neoadjuvant giredestrant—a novel nonsteroidal selective estrogen receptor (ER) degrader—to palbociclib showed a stronger antiproliferative effect...
Cytotoxic and Immune-Stimulatory Gene Therapy for Adults With Primary High-Grade Glioma
In a single-center, phase I, first-in-human trial reported in The Lancet Oncology, Yoshie Umemura, MD, and colleagues investigated treatment with the combination of two adenoviral vectors expressing HSV1-TK (Ad-hCMV-TK) and Flt3L (Ad-hCMV-Flt3L) in adults with primary high-grade glioma. As stated...
Risk Factors for Incident Heart Failure Among Cancer Survivors Aged 18 to 39
In a study reported in a research letter in JACC: CardioOncology, Hibler et al found that survivors of young adult cancers who were exposed to anthracyclines were at an increased risk of subsequent diagnosis of heart failure. Study Details The study involved electronic health record data from the...
